浙江地区幽门螺杆菌对喹诺酮类药物体外耐药情况分析

被引：3

作者：

潘杰 ^{[1
]}

周晴接 ^{[1
]}

姜洋 ^{[2
]}

杨宁敏 ^{[2
]}

张建中 ^{[3
]}

机构：

[1] 温州市中心医院消化内科

[2] 杭州致远医学检验所有限公司

[3] 北京, 中国疾病预防控制中心传染病预防控制所传染病预防控制国家重点实验室

来源：

中华微生物学和免疫学杂志 | 2015年 / 11期

关键词：

幽门螺杆菌; 喹诺酮; 药物敏感试验; 耐药性;

D O I：

暂无

中图分类号：

R446.5 [微生物学检验]; R573 [胃疾病];

学科分类号：

100201 [内科学]; 100208 [临床检验诊断学];

摘要：

目的分析幽门螺杆菌(Helicobacter pylori, HP)临床分离株对常用喹诺酮类抗生素的体外耐药情况, 为喹诺酮类药物在临床HP根除治疗中的应用提供依据。方法对2013年4月至2013年6月由浙江省不同地区多家医院胃镜标本中分离得到的713株HP菌株进行体外药物敏感试验, 分析其对左氧氟沙星与莫西沙星的耐药性。药物敏感试验根据美国实验室标准化协会(clinical and laboratory standards institute, CLSI)推荐方法, 采用耐药临界点药物琼脂稀释法进行药敏试验, 将抗生素溶液加入琼脂中稀释成相应的临界点浓度, 倾注平板, 接种菌悬液, 若接种点有菌生长则该菌株判读为耐药。结果 713株HP菌株对左氧氟沙星与莫西沙星耐药率均为19.50%, HP菌株对左氧氟沙星与莫西沙星的耐药情况完全一致。除金华地区外, 其他7个地区耐药率均达15%以上;其中, 温州地区最高, 达到26.40%, 明显高于金华地区(P<0.05), 与其他地区差异均无统计学意义(P>0.05)。结论同阿莫西林和呋喃唑酮相比, 浙江地区HP菌株对左氧氟沙星与莫西沙星的耐药率偏高。由于左氧氟沙星与莫西沙星两种抗生素药物耐药机制相同、药物作用靶点相似, 有相同的耐药特征。在临床HP根除时应避免左氧氟沙星与莫西沙星耐药时相互替换使用。

引用

共 10 条

[1]

Epigenetic regulation of DNA repair machinery in Helicobacter pylori-induced gastric carcinogenesis[J] Juliana Carvalho Santos;Marcelo Lima Ribeiro; World Journal of Gastroenterology 2015,

[2]

幽门螺杆菌抗生素耐药机制研究进展 [J].

李云振 ;

胡伟鹏 ;

高宏志 ;

王明席 .

微生物学通报, 2014, (05) :983-989

[3]

Antimicrobial resistance of Helicobacter pylori strains to five antibiotics; including levofloxacin; in Northwestern Turkey[J] Reyhan Caliskan;Hrisi Bahar Tokman;Yusuf Erzin;Suat Saribas;Pelin Yuksel;Bora Kazim Bolek;Ecehan Ozge Sevuk;Mehmet Demirci;Ozge Y?lmazli;Ozer Akgul;Fatma Kalayci;Huseyin Cakan;Barik Salih;Kadir Bal;Bekir Kocazeybek Revista da Sociedade Brasileira de Medicina Tropical 2015,

[4]

Comparison of levofloxacin- and moxifloxacin-based triple therapies with standard treatment in eradication of Helicobacter pylori as first-line therapy.[J] Rakici Halil;Ayaz Teslime;Akdogan Remzi Adnan;Bedir Recep Digestion 2014,

[5]

Effect of Fluoroquinolone Resistance on 14‐day Levofloxacin Triple and Triple Plus Bismuth Quadruple Therapy[J] Jingxian Liao;Qing Zheng;Xiao Liang;Wei Zhang;Qinjuan Sun;Wenzhong Liu;Shudong Xiao;David Y. Graham;Hong Lu Helicobacter 2013,

[6]

Antibiotic resistance of Helicobacter pylori isolated in the Southeast Coastal Region of China.[J] Su Peng;Li Youming;Li Hongzhang;Zhang Jiakun;Lin Lang;Wang Qunying;Guo Feng;Ji Zizhong;Mao Jibo;Tang Wuheng;Shi Zhengchao;Shao Wei;Mao Junliang;Zhu Xinjian;Zhang Xiaofeng;Tong Yuefeng;Tu Huimin;Jiang Mizu;Wang Zhiyong;Jin Fengzhe;Yang Ningmin;Zhang Jianzhong Helicobacter 2013,

[7]

Advantages of Moxifloxacin and Levofloxacin-based triple therapy for second-line treatments of persistent Helicobacter pylori infection: a meta analysis[J] Yuqin Li;Xiayue Huang;Linhua Yao;Ruihua Shi;Guoxin Zhang Wiener klinische Wochenschrift 2010,

[8]

Quinolone Resistance in Helicobacter pylori Isolates in Germany?[J] Erik Glocker;Hans Peter Stueger;Manfred Kist Antimicrobial Agents and Chemotherapy 2007,

[9]

Primary levofloxacin resistance and gyrA/B mutations among Helicobacter pylori in Japan.[J] Miyachi Hideyuki;Miki Ikuya;Aoyama Nobuo;Shirasaka Daisuke;Matsumoto Yuko;Toyoda Masanori;Mitani Toshifumi;Morita Yoshinori;Tamura Takao;Kinoshita Shohiro;Okano Yoshie;Kumagai Shunichi;Kasuga Masato Helicobacter 2006,

[10]

Single and double mutations in gyrA but not in gyrB are associated with low- and high-level fluoroquinolone resistance in Helicobacter pylori.[J] Tankovic Jacques;Lascols Christine;Sculo Quentin;Petit Jean-Claude;Soussy Claude-James Antimicrobial agents and chemotherapy 2003,

← 1 →